Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00996216 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT00996216 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 27 participants.
The verdict
NCT00996216, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy.
Interventions
- DRUG Eltrombopag
- DRUG Antiviral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00996216
The ClinicalTrials.gov registry entry for NCT00996216 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eltrombopag is the first listed.
NCT00996216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00996216 about?
NCT00996216 is a clinical study titled "Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390". The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanen...
What is the current status of trial NCT00996216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2009-09. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00996216?
The interventions under investigation include: Eltrombopag (DRUG), Antiviral therapy (DRUG).
Who is sponsoring clinical trial NCT00996216?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.